Quotient Sciences’ Post

At Endogena Therapeutics, leveraging AI has been integral to our approach since the early beginnings. In fact, it led us to discover our drug candidate EA-2353 for retinitis pigmentosa – a rare, degenerative eye disease. We are excited to see the pharmaceutical industry, including leading Swiss companies like Roche and Novartis, also harnessing AI to revolutionize drug discovery. This trend validates our early adoption and reinforces our commitment to pioneering regenerative medicine. Co-founders Matthias Steger PhD, MBA and Gisbert SCHNEIDER (ETH Zürich) are particularly inspired by how AI can enhance efficiency and innovation in bringing new treatments to patients. Discover more about AI's impact on pharma in this article from SWI swissinfo.ch: https://lnkd.in/gxr6S8SF. #AI #DrugDiscovery #Pharmaceuticals #Biotech #Innovation #RegenerativeMedicine #RetinitisPigmentosa #ArtificialIntelligence #HealthcareInnovation #MedicalResearch #FutureOfMedicine #SwissPharma #BigPharma #AIinHealthcare

Check this interesting article out about Combination Products. The technological advancements are really coming along and they are playing a huge role in Biopharma Innovation. This article nicely explains why! give it a read! #drugdelivery #pharmaceutical #biologics #biotech #innovation

How do you reduce the number of samples required for cell therapy release assays, when we have low yield of drug product itself? Join Jigesha Dholakia for her roundtable discussion on the topic at our Advanced Therapies Roundtable Xchange happening in #SanDiego, February 29th 2024. To view all facilitators, agendas, registration info and more, please visit: https://lnkd.in/dcuUeiVC Note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #manufacturing #therapeutics #therapies #oligonucleotide #genetherapies

How do you reduce the number of samples required for cell therapy release assays, when we have low yield of drug product itself? Join Jigesha Dholakia for her roundtable discussion on the topic at our Advanced Therapies Roundtable Xchange happening in #SanDiego, February 29th 2024. To view all facilitators, agendas, registration info and more, please visit: https://lnkd.in/exrsm4AC Note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #manufacturing #therapeutics #therapies #oligonucleotide #genetherapies

We'd like to thank DIA for their invaluable knowledge sharing in the article "AI Is Unearthing New Drug Candidates, But It Still Needs Human Oversight." At Acodis, we fully support the Human-in-the-Loop (HITL) approach, combining advanced AI with essential human expertise. This synergy enables us to help pharma organizations worldwide streamline drug development, reduce costs, and accelerate the delivery of life-saving treatments. 🌍💊 Thank you, DIA, for fostering innovation and collaboration in the pharmaceutical industry. 🚀 Read the Full Article here: https://lnkd.in/gNyndCZf

Thoughts on this? >> FDA Platform Designation Program Could Ease Path to Market for Gene-Editing Therapies - Precision Medicine Online >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #pharmaceutical #competitivemarketing

In this piece, a number of individuals try to answer the question “How are advancements in technology reshaping the roles and capabilities of CDMOs and CROs in the drug development life cycle?” #biopharmaceuticals #biotherapeutics #cellandgenetherapies #CDMO https://lnkd.in/eZrT_nn6

Why should pharmaceutical companies invest in discovery if there’s only a 5 to 10 percent chance that any given clinical trial will be successful? At Immunai, we’re creating the “Google Maps” of the immune system so that pharmaceuticals can predict exactly how a patient will respond to treatments. Combining AMICA™, our single-cell immunomics database, with AI/ML, we’re enhancing the precision of patient care and steering the pharmaceutical industry toward more successful clinical trials. Read more about our work in personalized healthcare from Zach Winn in MIT Technology Review: https://lnkd.in/ezJqxqj3

As a #raredisease researcher, I’m intrigued by how #artificialintelligence is already advancing progress for our industry. And as a physician, I’m especially excited about how leveraging this technology in clinical trials could expedite the development of new, more personalized therapies for patients. As #RareDiseaseDay approaches, I encourage you to check out my @Life Science Leader piece on learnings from integrating AI into the drug discovery process as we continue our mission to deliver therapies to patients living with complement-mediated and other rare diseases.

💡 How can we bridge the gap between preclinical studies and clinical success? This article, published in Nature Reviews Drug Discovery and written by MIMETAS' CEOs Jos Joore and Paul Vulto, explores how Organ-on-a-Chip (OoC) platform are impacting the pharmaceutical industry by doing just that. The publication details how these models offer precise platforms for better drug efficacy and safety predictions and help identify adverse drug effects and optimizing candidates. You'll also read how companies like Janssen, AstraZeneca, and Roche are leveraging OoCs for informed decision-making. Read the full article to see how OoCs are shaping the future of drug discovery and development. Read the article: https://lnkd.in/e-W_RtQ9 #DrugDiscovery #OrganOnChip #PharmaceuticalResearch #Biotech